After turning down previous unsolicited takeover offers by Valeant Pharmaceuticals, Allergan's board of directors has agreed to review a new proposal by the Canadian company which is due to expire on Aug. 15. The new offer would give Allergan's shareholders 0.83 Valeant shares and $72 in cash for each share ...
Buying a membership today will give you:
To continue reading this article register now.